Genentech persevERA breast cancer trial misses PFS goal
03/09/2026 –…
Roche persevERA breast cancer trial misses goal
Roche (OTCQX: RHHBY) reported that the phase III persevERA study of giredestrant plus palbociclib in 1L ER+/HER2- advanced…
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
H.C. Wainwright notes that Roche’s (RHHBY) persevERA trial “disappointingly” failed, though the firm does not view the frontline…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer](https://www.europesays.com/ch/wp-content/uploads/2026/03/964824-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival,…